MiR-22 also reduces epithelial cell damage via targeting the mammalian target of rapamycin (mTOR)/ hypoxia-inducible factor (HIF) feedback interaction pathway, enabling AKI recovery [106]. Here, MTOR is linked to acute kidney injury.